Every 10-Q that Jaguar Health, Inc. (JAGX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow JAGX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full JAGX filings page.
Jaguar Health, Inc. (JAGX) reports markedly improved results for the six months ended June 30, 2026. Total revenue was $21.5 million, up from $5.2 million a year earlier, driven largely by a jump in license revenue to $19.1 million. Product revenue contributed $2.4 million.
Operating performance strengthened: the company recorded a net loss of $4.1 million, compared with a $21.2 million loss in the prior-year period. Operating cash flow turned positive at $3.5 million versus a $13.5 million outflow. Jaguar also reduced notes payable significantly, with total liabilities falling to $29.3 million from $57.0 million, and stockholders’ equity moving from a deficit of $18.7 million at December 31, 2025 to positive $4.9 million at June 30, 2026, aided by preferred stock and warrant transactions.
Jaguar Health reported a sharp turnaround for the quarter ended March 31, 2026, driven by a major licensing transaction. Total revenue rose to $20.3 million from $2.2 million a year earlier, mainly from $19.0 million of license revenue under a new Mytesi and Canalevia license and supply agreement with Woodward, while product revenue declined.
The company posted net income of $8.7 million versus a $10.6 million loss in 2025, but common shareholders still saw a net loss of $7.0 million after $9.5 million of Series O preferred stock dividends and over $6.0 million of deemed preferred dividends. Cash was $7.3 million with $2.8 million in restricted cash, against total notes payable of about $33.2 million and a stockholders’ deficit of $15.8 million. Management disclosed recurring losses, a $391.1 million accumulated deficit and stated that these conditions raise substantial doubt about Jaguar’s ability to continue as a going concern over the next 12 months, even after receiving a $16.0 million upfront payment from a separate license and supply agreement.
Jaguar Health (JAGX) filed its Q3 2025 10‑Q, reporting total revenue of $3.083 million, essentially flat versus $3.108 million a year ago. Product sales were $3.041 million. The company posted a net loss of $9.648 million for the quarter and $30.804 million for the nine months.
Cash was $3.527 million at September 30, 2025, down from $8.002 million at year‑end. Current liabilities rose to $36.122 million (from $19.704 million), driven by notes payable current of $23.108 million. Total liabilities were $45.113 million, and stockholders’ equity was $4.359 million.
The company disclosed substantial doubt about its ability to continue as a going concern and plans to rely on additional financing and commercialization efforts. Financing inflows year‑to‑date included an ATM program ($6.331 million net), $3.445 million of convertible notes, and a PIPE for preferred shares ($2.377 million). As of November 14, 2025, there were 3,735,837 voting common shares outstanding and 9 non‑voting shares.
Jaguar Health, Inc. reported total net revenue of $2.98 million for the quarter ended June 30, 2025 (product revenue $2.94M), up from $2.72M a year earlier, and $5.19 million for the six months ended June 30, 2025 versus $5.07M in 2024. Operating expenses rose to $11.0 million for the quarter, producing an operating loss of $8.01 million and a net loss of $10.56 million (six-month net loss $21.16 million).
On the balance sheet, cash fell to $2.21 million at June 30, 2025 from $8.00M at year-end; total assets were $48.27 million and total liabilities $41.39 million. The Company discloses an accumulated deficit of $367.35 million and states its current cash balances are not sufficient to fund its operating plan through one year, noting substantial doubt about continuing as a going concern. Financing during the six months provided $7.62M (including a $3.25M ATM and $3.45M of convertible notes). Revenue remains concentrated: two specialty pharmacy customers accounted for roughly ~88% of product revenue.